Clinical trials: Vascular Disease Risk
Pulmonary Embolism
Diagnostic Accuracy of Arterial-alveolar Oxygen Gradient in Low Risk Patients With Suspected Pulmonary Embolism
Introduction: The diagnosis of pulmonary embolism (PE) is a challenge in the Emergency Department. D-dimer based diagnostic algorithms for PE have a very high sensitivity, but rely upon a vast amount of CT angiography and…
- Trial name
- DAGPE (NCT06043726)
- Testing
- Laboratory testing: D-dimeer and astrup
- Where
- Netherlands
- Volunteers
- 230 people
- Sponsor
- Franciscus Gasthuis
Chronic Kidney Diseases, Diabetes Mellitus
Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa
Prospective cross-sectional study at the outpatient clinic (OPC) of the Bagamoyo District Hospital (BDH) in Tanzania. Assessment of basic epidemiological data (Point prevalence and risk factors) on CKD with simple clinical…
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Hypertension, Tuberculosis
- Trial name
- RenalOne (NCT03458338)
- Testing
- estimated glomerular filtration rate and albuminuria
- Where
- Switzerland
- Volunteers
- 1,006 people
- Sponsor
- University Hospital, Basel, Switzerland
Cerebral Hemorrhage
Early Intensive Antihypertensive Treatment in High-Risk Population of intraCerebral Hemorrhage ExpanSion Predicted by Artificial Intelligence
The goal of this clinical trial is to clarify the efficacy, safety and feasibility of early intensive antihypertensive treantment in intracerebral hemorrhage (ICH) patients at high risk of hematoma expansion based on artificial…
- Trial name
- ARCHES (NCT06242938)
- Testing
- Early intensive antihypertensive treatment
- Volunteers
- 680 people
- Sponsor
- Beijing Tiantan Hospital
Intracranial Atherosclerosis
Asymptomatic Intracranial Atherosclerotic Disease in Pakistanis
The incidence of stroke has increased by 100% in the last four decades in developing countries like Pakistan. Intracranial atherosclerotic disease (ICAD) is the most frequent causative subtype of ischemic stroke in the world…
- Trial name
- AICAD (NCT02072876)
- Where
- 2 sites in Pakistan
- Volunteers
- 200 people
- Sponsor
- Aga Khan University
Stroke
A TargEted MAnageMent Intervention for Reducing Stroke Risk Factors in High Risk Ugandans
The proposed 2-phase project will first refine the TargetEd MAnageMent (TEAM) intervention to ensure acceptability across a broad range of Ugandans at risk for stroke and then test the effects of TEAM in reducing stroke risk in a…
- Trial name
- TEAM-U (NCT04685408)
- Testing
- TEAM, ETAU
- Where
- 3 sites in Uganda
- Volunteers
- 276 people
- Sponsor
- Case Western Reserve University
Coronary Heart Disease
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
The purpose of this study is to evaluate the safety and cholesterol lowering effects of MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a high risk of cardiovascular events and LDL-c…
- Trial name
- NCT01609140
- Testing
- MPSK3169A
- Where
- 73 sites in United States, Canada and 7 more
- Volunteers
- 248 people
- Sponsor
- Genentech, Inc.
Tracheostomy Complication, Trachea
Ultrasound Evaluation of the Vascular Anatomy of the Neck to Minimize the Accidental Risk of Vascular Puncture During Percutaneous Tracheostomy
Tracheostomy is a commonly performed procedure in Intensive Care and its incidence tends to increase over time as a consequence of the increase in chronic diseases and the average age of the population accessing Intensive Care.
- Trial name
- NCT06002178
- Testing
- Neck ultrasound
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University of Padova
Lifestyle Risk Reduction, Cholesterol, Elevated
Effect of a Customised Lifestyle Medicine Strategy on Lowering Blood Lipid Levels in Indian Physicians
Lifestyle medicine is a medical specialty that uses evidence-based therapeutic interventions to prevent, treat, and reverse chronic conditions.
- Conditions
- Lifestyle Risk Reduction, Cholesterol, Elevated, LDL Hyperlipoproteinemia, Hypertension
- Trial name
- CLIP (NCT06420817)
- Testing
- Indian version of a 'Portfolio' diet, Physical Activity, Intermittent fasting
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jubilee Mission Medical College and Research Institute
Acute Ischemic Stroke
An Application Provides Personalized Suggestions Based on Secondary Prevention Risk Factors to Stroke Patients
This study applied an application that provides personalized suggestions and explore the effect of this actual intervention on reducing the risk of stroke recurrence
- Trial name
- NCT07098143
- Testing
- Risk factor management
- Volunteers
- 5,092 people
- Sponsor
- Xuanwu Hospital, Beijing
Lung Neoplasms, Venous Thromboembolism
Venous Thromboembolism in Advanced Lung Cancer
This is a prospective observatory clinical study, aiming to establish and validate venous thromboembolism risk model in Chinese advanced non-small cell lung cancer.
- Trial name
- RIVAL (NCT03581708)
- Testing
- lung cancer
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Guangdong Provincial People's Hospital
Diabetes, Hypertension
Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes
Our study intends to test the efficacy of pharmacist-led group interventions on a weekly basis for 4-weeks, then on a monthly basis for 5 additional months to achieve concomitant reductions in hemoglobin A1c, lipids and blood…
- Conditions
- Diabetes, Hypertension, Dyslipidemia
- Trial name
- NCT00409240
- Testing
- MEDIC
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Providence VA Medical Center
Age-related Macular Degeneration, Coronary Artery Disease
Ranibizumab and the Risk of Arterial Thromboembolic Events
The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events.
- Conditions
- Age-related Macular Degeneration, Coronary Artery Disease, Cerebrovascular Disorders
- Trial name
- RATE (NCT01319188)
- Testing
- 0.5 mg of ranibizumab, 0.5 mg of ranibizumab + photodynamic therapy
- Where
- 2 sites in Netherlands, Russia
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Ural State Medical University
Atherosclerotic Cardiovascular Disease, STEMI
Real Life Lipid Management in Hospitals Not Participating in PENELOPE Trial - Control Population for PENELOPE
Guideline recommended evidence-based clinical care correlates with improved patient outcomes. In real life care, however, adherence to guideline recommendations remains suboptimal.
- Conditions
- Atherosclerotic Cardiovascular Disease, STEMI, Non STEMI
- Trial name
- PENELOPECTRL (NCT05659888)
- Where
- 13 sites in Netherlands
- Volunteers
- 827 people
- Sponsor
- Clinical Operations WCN B.V.
Diffuse Large B Cell Lymphoma, Thrombosis
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
Comparative Evaluation of Thrombotic Risk Models in DLBCL patients Objective: To assess the impact of thrombotic risk factors and compare the performance of existing predictive models (Khorana, Throly, Model IX) in Diffuse Large…
- Trial name
- PREDIC-TO (NCT06694779)
- Where
- Italy
- Volunteers
- 1,504 people
- Sponsor
- Fondazione IRCCS San Gerardo dei Tintori
Pulmonary Embolism Acute, Venous Thromboembolism (VTE)
Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism
This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a…
- Trial name
- APIX-PE (Apixa (NCT07774273)
- Testing
- Drug: Apixaban, Drug: Rivaroxaban
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- Combined military hospital lahore
Cardiovascular Diseases, Coronary Disease
Coronary Artery Disease Mechanisms in High Risk Families--Racial Difference
To examine whether differences existed between asymptomatic white and African Americans known to be at high risk for premature coronary artery disease (CAD) in risk factor distributions, prevalence of occult coronary disease, and…
- Conditions
- Cardiovascular Diseases, Coronary Disease, Heart Diseases
- Trial name
- NCT00005369
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myocardial Infarction, Vascular Stiffness
Impact of Peripheral Vascular Stiffness Assessment on Risk Prediction in Patients With Myocardial Infarction
Risk assessment after myocardial infarction is critical in daily practice and evolution toward heart failure especially diastolic heart failure remains a key issue.
- Conditions
- Myocardial Infarction, Vascular Stiffness, Heart Failure
- Trial name
- RIGID-MI (NCT04058782)
- Testing
- Imaging evaluation for vascular assessment
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Lille
Atherosclerosis, Cardiovascular Diseases
Semaglutide and Vascular Regeneration
SEMA-VR is a prospective, randomized, 6-month long, open-label study of semaglutide. Approximately 100 participants with type 2 diabetes and/or obesity will be randomized (1:1) to receive semaglutide at escalating doses (up to…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity
- Trial name
- SEMA-VR (NCT05870462)
- Testing
- Semaglutide Pen Injector
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Canadian Medical and Surgical Knowledge Translation Research Group
Ischemic Heart Disease, Atrial Fibrillation
Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients
Preliminary experiences suggest that intermittent anticoagulation guided by continuous electrocardiographic monitoring can reduce the incidence of bleeding in patients with episodes of atrial fibrillation.
- Trial name
- INTERMITTENT (NCT04151680)
- Testing
- Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban, Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Stable Angina, Ischemic Heart Disease Silent
A Randomized Clinical Evaluation of the BioFreedom™ Stent
The purpose of this study is to demonstrate that a BioFreedom™ Drug Coated Stent is non-inferior to a bare metal stent at one year as measured by the composite safety endpoint of cardiovascular death, myocardial infarction and…
- Conditions
- Stable Angina, Ischemic Heart Disease Silent, ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction, In-stent Coronary Artery Restenosis
- Trial name
- Leaders Free (NCT01623180)
- Testing
- Biofreedom™ Drug Coated Stent (DCS), Gazelle™ Bare Metal Coronary Stent (BMS)
- Where
- Switzerland
- Volunteers
- 2,456 people
- Sponsor
- Biosensors Europe SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.